A prospective trial to evaluate the safety and efficacy of pravastatin for the treatment of refractory chronic graft-versus-host disease
This prospective study evaluates the safety and efficacy of pravastatin for the treatment of chronic graft-versus-host disease (GVHD). We included 18 patients with refractory chronic GVHD. Oral pravastatin was started at 10 mg/day, and the dose was increased up to 40 mg/day in 4 weeks. This maximum...
Gespeichert in:
Veröffentlicht in: | Transplantation 2005-02, Vol.79 (3), p.372-374 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 374 |
---|---|
container_issue | 3 |
container_start_page | 372 |
container_title | Transplantation |
container_volume | 79 |
creator | HORI, Akiko KANDA, Yoshinobu KOJIMA, Rie HAMAKI, Tamae SAKIYAMA, Michiyo KAMI, Masahiro MAKIMOTO, Atsushi TANOSAKI, Ryuji TAKAUE, Yoichi HIRAI, Hisamaru GOYAMA, Susumu ONISHI, Yasushi KOMENO, Yukiko MITANI, Kinuko KISHI, Yukiko OGAWA, Seishi IMATAKI, Osamu CHIBA, Shigeru |
description | This prospective study evaluates the safety and efficacy of pravastatin for the treatment of chronic graft-versus-host disease (GVHD). We included 18 patients with refractory chronic GVHD. Oral pravastatin was started at 10 mg/day, and the dose was increased up to 40 mg/day in 4 weeks. This maximum dose was administered over 8 weeks. There were no severe adverse events caused by pravastatin. A clinical response was observed in the skin score in two patients, mouth score in five patients, eye score in two patients, liver score in three patients, platelet count score in one patient, and weight loss in two patients. The overall response rate was 28%. Immunophenotypic analyses showed that T-helper (Th)1 cells were dominant in all but one patient before treatment and that the Th1/Th2 ratio tended to be lower in the responders than in the nonresponders. A randomized controlled trial is warranted to evaluate the efficacy of pravastatin against chronic GVHD. |
doi_str_mv | 10.1097/01.tp.0000151001.64189.1d |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_19280214</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19280214</sourcerecordid><originalsourceid>FETCH-LOGICAL-c522t-adb72671d9796ad7a9d5072b40079846201054a317e6d58cf45027060e4e2be23</originalsourceid><addsrcrecordid>eNpFkc2O1DAQhC0EYoeFV0DmALeEbseO4-Nq-ZVWgsNytnqcDhOUSQbbGWnegMfGuzvS9MEtWV_Zqioh3iHUCM5-BKzzoYYyaLAcdauxczX2z8QGTaOrFjp4LjYAGitsGnslXqX0p_CmsfaluELTOmet3oh_N_IQl3TgkMcjyxxHmmReJB9pWimXmx3LRAPnk6S5lzwMY6BwkstQhHSklCmPsxyW-IjmyJT3POcHIPIQKeQlnmTYxWUeg_wdacjVkWNaU7VbUpb9mJgSvxYvBpoSvznva_Hry-f722_V3Y-v329v7qpglMoV9VurWou9s66l3pLrDVi11QDWdbpVgGA0NWi57U0XBm1AWWiBNastq-ZafHh6t9j-u3LKfj-mwNNEMy9r8uhUBwp1Ad0TGEo-qVjxhzjuKZ48gn-owQP6-5_-UoN_rMHjp6J9e_5k3e65vyjPuRfg_RmgFGgqMc1hTBeuNapguvkPjL6Svw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19280214</pqid></control><display><type>article</type><title>A prospective trial to evaluate the safety and efficacy of pravastatin for the treatment of refractory chronic graft-versus-host disease</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>HORI, Akiko ; KANDA, Yoshinobu ; KOJIMA, Rie ; HAMAKI, Tamae ; SAKIYAMA, Michiyo ; KAMI, Masahiro ; MAKIMOTO, Atsushi ; TANOSAKI, Ryuji ; TAKAUE, Yoichi ; HIRAI, Hisamaru ; GOYAMA, Susumu ; ONISHI, Yasushi ; KOMENO, Yukiko ; MITANI, Kinuko ; KISHI, Yukiko ; OGAWA, Seishi ; IMATAKI, Osamu ; CHIBA, Shigeru</creator><creatorcontrib>HORI, Akiko ; KANDA, Yoshinobu ; KOJIMA, Rie ; HAMAKI, Tamae ; SAKIYAMA, Michiyo ; KAMI, Masahiro ; MAKIMOTO, Atsushi ; TANOSAKI, Ryuji ; TAKAUE, Yoichi ; HIRAI, Hisamaru ; GOYAMA, Susumu ; ONISHI, Yasushi ; KOMENO, Yukiko ; MITANI, Kinuko ; KISHI, Yukiko ; OGAWA, Seishi ; IMATAKI, Osamu ; CHIBA, Shigeru ; Japan Hematology and Oncology Clinical Study Group</creatorcontrib><description>This prospective study evaluates the safety and efficacy of pravastatin for the treatment of chronic graft-versus-host disease (GVHD). We included 18 patients with refractory chronic GVHD. Oral pravastatin was started at 10 mg/day, and the dose was increased up to 40 mg/day in 4 weeks. This maximum dose was administered over 8 weeks. There were no severe adverse events caused by pravastatin. A clinical response was observed in the skin score in two patients, mouth score in five patients, eye score in two patients, liver score in three patients, platelet count score in one patient, and weight loss in two patients. The overall response rate was 28%. Immunophenotypic analyses showed that T-helper (Th)1 cells were dominant in all but one patient before treatment and that the Th1/Th2 ratio tended to be lower in the responders than in the nonresponders. A randomized controlled trial is warranted to evaluate the efficacy of pravastatin against chronic GVHD.</description><identifier>ISSN: 0041-1337</identifier><identifier>EISSN: 1534-6080</identifier><identifier>DOI: 10.1097/01.tp.0000151001.64189.1d</identifier><identifier>PMID: 15699774</identifier><identifier>CODEN: TRPLAU</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott</publisher><subject>Biological and medical sciences ; Chronic Disease ; Fundamental and applied biological sciences. Psychology ; Fundamental immunology ; Graft vs Host Disease - drug therapy ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Medical sciences ; Pravastatin - adverse effects ; Pravastatin - therapeutic use ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Th1 Cells - drug effects ; Th1 Cells - immunology ; Th2 Cells - drug effects ; Th2 Cells - immunology ; Tissue, organ and graft immunology</subject><ispartof>Transplantation, 2005-02, Vol.79 (3), p.372-374</ispartof><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c522t-adb72671d9796ad7a9d5072b40079846201054a317e6d58cf45027060e4e2be23</citedby><cites>FETCH-LOGICAL-c522t-adb72671d9796ad7a9d5072b40079846201054a317e6d58cf45027060e4e2be23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16527744$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15699774$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HORI, Akiko</creatorcontrib><creatorcontrib>KANDA, Yoshinobu</creatorcontrib><creatorcontrib>KOJIMA, Rie</creatorcontrib><creatorcontrib>HAMAKI, Tamae</creatorcontrib><creatorcontrib>SAKIYAMA, Michiyo</creatorcontrib><creatorcontrib>KAMI, Masahiro</creatorcontrib><creatorcontrib>MAKIMOTO, Atsushi</creatorcontrib><creatorcontrib>TANOSAKI, Ryuji</creatorcontrib><creatorcontrib>TAKAUE, Yoichi</creatorcontrib><creatorcontrib>HIRAI, Hisamaru</creatorcontrib><creatorcontrib>GOYAMA, Susumu</creatorcontrib><creatorcontrib>ONISHI, Yasushi</creatorcontrib><creatorcontrib>KOMENO, Yukiko</creatorcontrib><creatorcontrib>MITANI, Kinuko</creatorcontrib><creatorcontrib>KISHI, Yukiko</creatorcontrib><creatorcontrib>OGAWA, Seishi</creatorcontrib><creatorcontrib>IMATAKI, Osamu</creatorcontrib><creatorcontrib>CHIBA, Shigeru</creatorcontrib><creatorcontrib>Japan Hematology and Oncology Clinical Study Group</creatorcontrib><title>A prospective trial to evaluate the safety and efficacy of pravastatin for the treatment of refractory chronic graft-versus-host disease</title><title>Transplantation</title><addtitle>Transplantation</addtitle><description>This prospective study evaluates the safety and efficacy of pravastatin for the treatment of chronic graft-versus-host disease (GVHD). We included 18 patients with refractory chronic GVHD. Oral pravastatin was started at 10 mg/day, and the dose was increased up to 40 mg/day in 4 weeks. This maximum dose was administered over 8 weeks. There were no severe adverse events caused by pravastatin. A clinical response was observed in the skin score in two patients, mouth score in five patients, eye score in two patients, liver score in three patients, platelet count score in one patient, and weight loss in two patients. The overall response rate was 28%. Immunophenotypic analyses showed that T-helper (Th)1 cells were dominant in all but one patient before treatment and that the Th1/Th2 ratio tended to be lower in the responders than in the nonresponders. A randomized controlled trial is warranted to evaluate the efficacy of pravastatin against chronic GVHD.</description><subject>Biological and medical sciences</subject><subject>Chronic Disease</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Fundamental immunology</subject><subject>Graft vs Host Disease - drug therapy</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Medical sciences</subject><subject>Pravastatin - adverse effects</subject><subject>Pravastatin - therapeutic use</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>Th1 Cells - drug effects</subject><subject>Th1 Cells - immunology</subject><subject>Th2 Cells - drug effects</subject><subject>Th2 Cells - immunology</subject><subject>Tissue, organ and graft immunology</subject><issn>0041-1337</issn><issn>1534-6080</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkc2O1DAQhC0EYoeFV0DmALeEbseO4-Nq-ZVWgsNytnqcDhOUSQbbGWnegMfGuzvS9MEtWV_Zqioh3iHUCM5-BKzzoYYyaLAcdauxczX2z8QGTaOrFjp4LjYAGitsGnslXqX0p_CmsfaluELTOmet3oh_N_IQl3TgkMcjyxxHmmReJB9pWimXmx3LRAPnk6S5lzwMY6BwkstQhHSklCmPsxyW-IjmyJT3POcHIPIQKeQlnmTYxWUeg_wdacjVkWNaU7VbUpb9mJgSvxYvBpoSvznva_Hry-f722_V3Y-v329v7qpglMoV9VurWou9s66l3pLrDVi11QDWdbpVgGA0NWi57U0XBm1AWWiBNastq-ZafHh6t9j-u3LKfj-mwNNEMy9r8uhUBwp1Ad0TGEo-qVjxhzjuKZ48gn-owQP6-5_-UoN_rMHjp6J9e_5k3e65vyjPuRfg_RmgFGgqMc1hTBeuNapguvkPjL6Svw</recordid><startdate>20050215</startdate><enddate>20050215</enddate><creator>HORI, Akiko</creator><creator>KANDA, Yoshinobu</creator><creator>KOJIMA, Rie</creator><creator>HAMAKI, Tamae</creator><creator>SAKIYAMA, Michiyo</creator><creator>KAMI, Masahiro</creator><creator>MAKIMOTO, Atsushi</creator><creator>TANOSAKI, Ryuji</creator><creator>TAKAUE, Yoichi</creator><creator>HIRAI, Hisamaru</creator><creator>GOYAMA, Susumu</creator><creator>ONISHI, Yasushi</creator><creator>KOMENO, Yukiko</creator><creator>MITANI, Kinuko</creator><creator>KISHI, Yukiko</creator><creator>OGAWA, Seishi</creator><creator>IMATAKI, Osamu</creator><creator>CHIBA, Shigeru</creator><general>Lippincott</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>20050215</creationdate><title>A prospective trial to evaluate the safety and efficacy of pravastatin for the treatment of refractory chronic graft-versus-host disease</title><author>HORI, Akiko ; KANDA, Yoshinobu ; KOJIMA, Rie ; HAMAKI, Tamae ; SAKIYAMA, Michiyo ; KAMI, Masahiro ; MAKIMOTO, Atsushi ; TANOSAKI, Ryuji ; TAKAUE, Yoichi ; HIRAI, Hisamaru ; GOYAMA, Susumu ; ONISHI, Yasushi ; KOMENO, Yukiko ; MITANI, Kinuko ; KISHI, Yukiko ; OGAWA, Seishi ; IMATAKI, Osamu ; CHIBA, Shigeru</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c522t-adb72671d9796ad7a9d5072b40079846201054a317e6d58cf45027060e4e2be23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Biological and medical sciences</topic><topic>Chronic Disease</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Fundamental immunology</topic><topic>Graft vs Host Disease - drug therapy</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Medical sciences</topic><topic>Pravastatin - adverse effects</topic><topic>Pravastatin - therapeutic use</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>Th1 Cells - drug effects</topic><topic>Th1 Cells - immunology</topic><topic>Th2 Cells - drug effects</topic><topic>Th2 Cells - immunology</topic><topic>Tissue, organ and graft immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HORI, Akiko</creatorcontrib><creatorcontrib>KANDA, Yoshinobu</creatorcontrib><creatorcontrib>KOJIMA, Rie</creatorcontrib><creatorcontrib>HAMAKI, Tamae</creatorcontrib><creatorcontrib>SAKIYAMA, Michiyo</creatorcontrib><creatorcontrib>KAMI, Masahiro</creatorcontrib><creatorcontrib>MAKIMOTO, Atsushi</creatorcontrib><creatorcontrib>TANOSAKI, Ryuji</creatorcontrib><creatorcontrib>TAKAUE, Yoichi</creatorcontrib><creatorcontrib>HIRAI, Hisamaru</creatorcontrib><creatorcontrib>GOYAMA, Susumu</creatorcontrib><creatorcontrib>ONISHI, Yasushi</creatorcontrib><creatorcontrib>KOMENO, Yukiko</creatorcontrib><creatorcontrib>MITANI, Kinuko</creatorcontrib><creatorcontrib>KISHI, Yukiko</creatorcontrib><creatorcontrib>OGAWA, Seishi</creatorcontrib><creatorcontrib>IMATAKI, Osamu</creatorcontrib><creatorcontrib>CHIBA, Shigeru</creatorcontrib><creatorcontrib>Japan Hematology and Oncology Clinical Study Group</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HORI, Akiko</au><au>KANDA, Yoshinobu</au><au>KOJIMA, Rie</au><au>HAMAKI, Tamae</au><au>SAKIYAMA, Michiyo</au><au>KAMI, Masahiro</au><au>MAKIMOTO, Atsushi</au><au>TANOSAKI, Ryuji</au><au>TAKAUE, Yoichi</au><au>HIRAI, Hisamaru</au><au>GOYAMA, Susumu</au><au>ONISHI, Yasushi</au><au>KOMENO, Yukiko</au><au>MITANI, Kinuko</au><au>KISHI, Yukiko</au><au>OGAWA, Seishi</au><au>IMATAKI, Osamu</au><au>CHIBA, Shigeru</au><aucorp>Japan Hematology and Oncology Clinical Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A prospective trial to evaluate the safety and efficacy of pravastatin for the treatment of refractory chronic graft-versus-host disease</atitle><jtitle>Transplantation</jtitle><addtitle>Transplantation</addtitle><date>2005-02-15</date><risdate>2005</risdate><volume>79</volume><issue>3</issue><spage>372</spage><epage>374</epage><pages>372-374</pages><issn>0041-1337</issn><eissn>1534-6080</eissn><coden>TRPLAU</coden><abstract>This prospective study evaluates the safety and efficacy of pravastatin for the treatment of chronic graft-versus-host disease (GVHD). We included 18 patients with refractory chronic GVHD. Oral pravastatin was started at 10 mg/day, and the dose was increased up to 40 mg/day in 4 weeks. This maximum dose was administered over 8 weeks. There were no severe adverse events caused by pravastatin. A clinical response was observed in the skin score in two patients, mouth score in five patients, eye score in two patients, liver score in three patients, platelet count score in one patient, and weight loss in two patients. The overall response rate was 28%. Immunophenotypic analyses showed that T-helper (Th)1 cells were dominant in all but one patient before treatment and that the Th1/Th2 ratio tended to be lower in the responders than in the nonresponders. A randomized controlled trial is warranted to evaluate the efficacy of pravastatin against chronic GVHD.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott</pub><pmid>15699774</pmid><doi>10.1097/01.tp.0000151001.64189.1d</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0041-1337 |
ispartof | Transplantation, 2005-02, Vol.79 (3), p.372-374 |
issn | 0041-1337 1534-6080 |
language | eng |
recordid | cdi_proquest_miscellaneous_19280214 |
source | MEDLINE; Journals@Ovid Complete |
subjects | Biological and medical sciences Chronic Disease Fundamental and applied biological sciences. Psychology Fundamental immunology Graft vs Host Disease - drug therapy Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Medical sciences Pravastatin - adverse effects Pravastatin - therapeutic use Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Th1 Cells - drug effects Th1 Cells - immunology Th2 Cells - drug effects Th2 Cells - immunology Tissue, organ and graft immunology |
title | A prospective trial to evaluate the safety and efficacy of pravastatin for the treatment of refractory chronic graft-versus-host disease |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T03%3A24%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20prospective%20trial%20to%20evaluate%20the%20safety%20and%20efficacy%20of%20pravastatin%20for%20the%20treatment%20of%20refractory%20chronic%20graft-versus-host%20disease&rft.jtitle=Transplantation&rft.au=HORI,%20Akiko&rft.aucorp=Japan%20Hematology%20and%20Oncology%20Clinical%20Study%20Group&rft.date=2005-02-15&rft.volume=79&rft.issue=3&rft.spage=372&rft.epage=374&rft.pages=372-374&rft.issn=0041-1337&rft.eissn=1534-6080&rft.coden=TRPLAU&rft_id=info:doi/10.1097/01.tp.0000151001.64189.1d&rft_dat=%3Cproquest_cross%3E19280214%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19280214&rft_id=info:pmid/15699774&rfr_iscdi=true |